Growing revenue signals Recent quarterly revenue trends show a modest increase but guidance cut for the year highlights pressure from weaker collection rates and a major customer shifting testing in-house. This suggests opportunities to upsell or cross-sell to existing customers by expanding service lines, data integration, and managed testing programs to stabilize and grow revenue.

Strategic acquisitions Acquisitions of StrataDx and Bako Diagnostics indicate a consolidation strategy to expand lab capacity and pathology services. This presents a chance to offer integration services, transformation consulting, and scalable genomic testing workflows to newly combined laboratories.

Partnership momentum Partnership with Foundation Medicine and the oncology focus imply a strong interest in co-developed tests and platform-enabled diagnostics. This creates sales opportunities around joint development, validation partnerships, and leveraging Fulgent's technology platform for new panels or companion tests.

Platform-led offerings A diversified testing menu across oncology, pathology, rare diseases, and reproductive health, underpinned by a core technology platform, signals potential for enterprise-wide deployment and integration deals with clinics, hospitals, and health systems seeking standardized genomic testing across departments.

Compliance and reliability Being CLIA-certified and CAP-accredited reinforces trust for large customers and payers. Leverage this to pursue revenue-sharing models, managed services, and long-term contracts with insurers and healthcare providers prioritizing quality, turnaround times, and regulatory compliance.